Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:20 a.m. ET. The presentation will be available for live streaming on their website. Regeneron is known for developing life-saving medications and has eight FDA-approved treatments. Their innovative drug development processes include proprietary technologies like VelociSuite and the Regeneron Genetics Center, contributing to their robust pipeline targeting serious health issues.

Positive

• Scheduled presentation at a prestigious healthcare conference, which can enhance visibility and investor confidence.
• Established reputation with eight FDA-approved treatments, indicating strong product validation and market presence.
• Innovative proprietary technologies, such as VelociSuite, suggesting continued potential for successful drug development.

Negative

• None.

TARRYTOWN, N.Y., Dec. 16, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 39^th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021.  The presentation is scheduled for 8:20 a.m. Eastern Time and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm.  An archived version of the webcast will be available for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite^® technologies, such as VelocImmune^®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations 
Justin Holko 
914.847.7786
justin.holko@regeneron.com                            

Corporate Communications
Hala Mirza
914.847.3422
hala.mirza@regeneron.com

View original content:http://www.prnewswire.com/news-releases/regeneron-announces-presentation-at-the-39th-annual-jp-morgan-healthcare-conference-301193601.html

SOURCE Regeneron Pharmaceuticals, Inc.

FAQ

When is Regeneron's presentation at the J.P. Morgan Healthcare Conference?

Regeneron's presentation is scheduled for January 11, 2021, at 8:20 a.m. Eastern Time.

How can I access Regeneron's conference presentation?

The presentation can be accessed live on Regeneron's 'Investors & Media' page on their website.

What is Regeneron Pharmaceuticals known for?

Regeneron is known for inventing life-transforming medicines, having eight FDA-approved treatments and a strong pipeline.

What technologies does Regeneron use in drug development?

Regeneron uses proprietary technologies such as VelociSuite, which includes VelocImmune for optimized antibody development.

What type of diseases does Regeneron target with its medicines?

Regeneron's medicines aim to help patients with eye diseases, cancer, cardiovascular issues, and rare diseases.